NexDx Raises $2.1M in Series B Financing | GenomeWeb

NEW YORK (GenomeWeb News) – Start-up molecular diagnostics firm NexDx said today it has completed its Series B financing round, bringing in $2.1 million.

The round was led by founding investor City Hill Ventures. Silicon Valley Bank also is providing a $500,000 capital term loan to the San Diego-based company. The funding will be used to support continued R&D and further NexDx's lead diagnostic test for rheumatoid arthritis into analytical and clinical validation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.